The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway

The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway

Drug repositioning has recently emerged as a strategy for developing new treatments at low cost. In this study, we used a library of approved drugs to screen for compounds that suppress cardiomyocyte hypertrophy. We identified the antiplatelet drug sarpogrelate, a selective serotonin-2A (5-HT<sub...

Full description

Bibliographic Details
Main Authors: Kana Shimizu, Yoichi Sunagawa, Masafumi Funamoto, Hiroki Honda, Yasufumi Katanasaka, Noriyuki Murai, Yuto Kawase, Yuta Hirako, Takahiro Katagiri, Harumi Yabe, Satoshi Shimizu, Nurmila Sari, Hiromichi Wada, Koji Hasegawa, Tatsuya Morimoto
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Pharmaceuticals
Subjects:
sarpogrelate
5-HT<sub>2A</sub> receptor
drug repositioning
ERK1/2–GATA4 pathway
heart failure
Online Access:https://www.mdpi.com/1424-8247/14/12/1268

Similar Items

Similar Items